helicobacter pylori infection
Conditions
Interventions
Group A:BIFICO t.i.d for 30 days + esomeprazole b.i.d + bismuth potassium citrate b.i.d + amoxicillin b.i.d + furazolidone b.i.d for 14 days
Group B:esomeprazole b.i.d + bismuth potassium citrate b.i.d + amoxicillin b.i.d + furazolidone b.i.d for 14 days
Sponsors
The First Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged 18 or older, female and male; 2. Patients who failed to eradicate Hp = 2 times; 3. After 3-6 months of eradication failure, the 13C breath test was positive and confirmed as Hp persistent infection; 4. Voluntarily participate in and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. History of gastric surgery: partial gastrectomy, gastroplasty, and vagectomy (but simple ulcer perforation repair or ulcer suture to stop bleeding can be included). 2. Patients who had taken antibiotics, probiotics or prebiotics 4 weeks before treatment, H2RA, PPI or bismuth 2 weeks before treatment and glucocorticoids, immunosuppressants or non-steroidal anti-inflammatory drugs 3 months before treatment. 3. Pregnant or lactating women, or women of reproductive age who do not take reliable contraception. 4. Patients who cannot avoid drinking during the trial. 5. Those who have severe primary diseases of the liver, kidney, heart, brain, lung, endocrine system and hematopoietic system but fail to control effectively. 6. There are contraindications to the test drugs. 7. Patients who require anticoagulant therapy or long-term use of non-steroidal anti-inflammatory drugs (NSAIDs). 8. Subjects with difficulty swallowing. 9. Patients with Zollinger-Ellison syndrome. 10. Patients with malignant tumors. 11. Those who participated in other clinical trials within the first three months of enrollment. 12. Patients who are not suitable for clinical trials as judged by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the effect of BIFICO combined with quadruple therapy on gastrointestinal microecology; | — |
Secondary
| Measure | Time frame |
|---|---|
| symptom remission rate;H. pylori eradication rate;the rate of side effects;the differences in baseline gastric flora between patients with successful and failed eradication; | — |
Countries
China
Contacts
Public ContactNonghua Lv
The First Affiliated Hospital of Nanchang University
Outcome results
None listed